CytoSorbents Corporation

(NASDAQ:CTSO) Trade

By |

Equities News

Company chart and information is provided by TradingView based on 15-minute-delayed data.


Profile

CytoSorbents Corp is a critical care immunotherapy leader commercializing its European Union approved CytoSorb blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients in around 55 countries. The company is conducting its pivotal REFRESH 2 - AKI cardiac surgery trial, designed to support U.S. FDA approval. The company's product portfolio consists of CytoSorb, ContrastSorb, VetResQ, HemoDefend, K ontrol, and DrugSorb. The company has around 19 issued U.S. patents, multiple patents issued internationally, and a broad patent application portfolio pending.

Contact Information

Website: www.cytosorbents.com
Email: avogel@cytosorbents.com
Main Phone: +1 732 329-8885
Address: 7 Deer Park Drive
Address 2: Suite K
State: NJ
City / Town: Monmouth Junction
Country: US
Postal Code: 08852

Issuer Information

Exchange: NSC
CEO: Phillip P. Chan
Employees: 195
NAICS: Medical Laboratories(621511)

Equities News

(%)
Company data no longer available
Last Price N/A Change $ N/A Change % N/A Tick N/A
Bid N/A Bid Size N/A Ask N/A Ask Size N/A
Open N/A High N/A Low N/A Prev Close N/A
Last Trade Volume N/A 52 Wk Hi N/A 52 Wk Low N/A
Market Cap N/A Ex-Div Date N/A Div Rate N/A Yield N/A
Shares N/A EPS (TTM) N/A PE Ratio N/A Exchange N/A